ELVN Stock Forecast & Price Target

Enliven Therapeutics is viewed favorably because ELVN-001 has shown strong early efficacy in heavily pretreated CML, with a 61% overall major molecular response by 24 weeks at 80 mg and meaningful deep molecular responses, suggesting real potential in a difficult 2L+ population. The data also look competitive across prior therapy subgroups, including patients previously exposed to asciminib, which supports the thesis that ELVN-001 can carve out a differentiated niche even as rival programs advance in newly diagnosed Ph+ CML. Combined with the updated 70% probability of approval in the 2L+ setting and the recent equity offering that strengthens funding flexibility, the company appears better positioned to progress its clinical and commercial strategy.

Enliven Therapeutics is a clinical-stage biopharmaceutical company facing substantial execution risk because its value depends heavily on ELVN-001 advancing successfully, yet the company itself highlights clinical setbacks, failure to reach pivotal assessment, and possible regulatory approval problems as key threats. Its DCF framework assumes an 11% discount rate, 1.0% terminal growth, a 25.4% tax rate, and only a 75% probability of approval for ELVN-001, underscoring the uncertainty embedded in the pipeline. Even with about $884.8M in pro forma cash as of end-1Q26 and an implied $3.66B firm value, downside remains elevated from competitive pressure, weaker-than-expected product uptake, pricing and reimbursement risk, and potential dilution.